Ronald Taylor

Prof. Ronald Taylor

Emeritus Professor
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2017 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
Chang Han LeeChang Han Lee
Chang Han Lee
GRGabrielle Romain
Gabrielle Romain
WYWupeng Yan
Wupeng Yan
MWMakiko Watanabe
Makiko Watanabe
WCWissam Charab
Wissam Charab
GGGeorge Georgiou
George Georgiou

1 August 2008 in Current Opinion in Immunology
Verified
Journal Article
Closed access
Ronald TaylorRonald Taylor
Ronald Taylor
MLMargaret Lindorfer
Margaret Lindorfer

1 February 2007 in Nature Clinical Practice Rheumatology
Verified
Journal Article
Closed access
Ronald TaylorRonald Taylor
Ronald Taylor
MLMargaret A Lindorfer
Margaret A Lindorfer

15 November 2006 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MWMichael E Williams
Michael E Williams
JDJohn J. Densmore
John J. Densmore
APAndrew W. Pawluczkowycz
Andrew W. Pawluczkowycz
PBPaul V. Beum
Paul V. Beum
AKAdam D. Kennedy
Adam D. Kennedy
Ronald TaylorRonald Taylor
Ronald Taylor
Treatment of chronic lymphocytic leukemia (CLL) patients with standard dose infusion of rituximab (RTX), 375 mg/m2, induces clearance of malignant cells from peripheral blood after infusion of 30 mg of RTX. After completion of the full RTX infusion, substantial recrudescence of CLL cells occurs, and these cells have lost >90% of CD20. To gain insight into mechanism(s) of CD20 loss, we investigated the hypothesis that thrice-weekly low-dose RTX (20 or 60 mg/m2) treatment for CLL over 4 wk would preserve CD20 and enhance leukemic cell clearance. During initial infusions in all 12 patients, the first 30 mg of RTX promoted clearance of >75% leukemic cells. Four of six patients receiving 20 mg/m2 RTX retained ≥50% CD20, and additional RTX infusions promoted further cell clearance. However, four of six patients receiving 60 mg/m2 had CD20 levels <20% baseline 2 days after initial infusions, and additional RTX infusions were less effective, presumably due to epitope loss. Our results suggest that when a threshold RTX dose is exceeded, recrudesced RTX-opsonized cells are not cleared, due to saturation of the mononuclear phagocytic system, but instead are shaved of RTX-CD20 complexes by acceptor cells. Thrice-weekly low-dose RTX may promote enhanced clearance of circulating CLL cells by preserving CD20.

1 April 2012 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
FBFrank J. Beurskens
Frank J. Beurskens
MLMargaret A Lindorfer
Margaret A Lindorfer
MFMohammed Farooqui
Mohammed Farooqui
PBPaul V. Beum
Paul V. Beum
PEPatrick Engelberts
Patrick Engelberts
Ronald TaylorRonald Taylor
Ronald Taylor
The CD20 mAb ofatumumab (OFA) induces complement-mediated lysis of B cells. In an investigator-initiated phase II trial of OFA plus chemotherapy for chronic lymphocytic leukemia (CLL), OFA treatment promoted partial CLL B cell depletion that coincided with reduced complement titers. Remaining CLL B cells circulated with bound OFA and covalently bound complement breakdown product C3d, indicative of ongoing complement activation. Presumably, neither complement- nor effector cell-based mechanisms were sufficiently robust to clear these remaining B cells. Instead, almost all of the bound OFA and CD20 was removed from the cells, in accordance with previous clinical studies that demonstrated comparable loss of CD20 from B cells after treatment of CLL patients with rituximab. In vitro experiments with OFA and rituximab addressing these observations suggest that host effector mechanisms that support mAb-mediated lysis and tumor cell clearance are finite, and they can be saturated or exhausted at high B cell burdens, particularly at high mAb concentrations. Interestingly, only a fraction of available complement was required to kill cells with CD20 mAbs, and killing could be tuned by titrating the mAb concentration. Consequently, maximal B cell killing of an initial and secondary B cell challenge was achieved with intermediate mAb concentrations, whereas high concentrations promoted lower overall killing. Therefore, mAb therapies that rely substantially on effector mechanisms subject to exhaustion, including complement, may benefit from lower, more frequent dosing schemes optimized to sustain and maximize killing by cytotoxic immune effector systems.

28 October 2020 in Antibodies
Verified
Journal Article
Open access
PDF file
Josee GolayJosee Golay
Josee Golay
Ronald TaylorRonald Taylor
Ronald Taylor
Unconjugated anti-cancer IgG1 monoclonal antibodies (mAbs) activate antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages, and these activities are thought to be important mechanisms of action for many of these mAbs in vivo. Several mAbs also activate the classical complement pathway and promote complement-dependent cytotoxicity (CDC), although with very different levels of efficacy, depending on the mAb, the target antigen, and the tumor type. Recent studies have unraveled the various structural factors that define why some IgG1 mAbs are strong mediators of CDC, whereas others are not. The role of complement activation and membrane inhibitors expressed by tumor cells, most notably CD55 and CD59, has also been quite extensively studied, but how much these affect the resistance of tumors in vivo to IgG1 therapeutic mAbs still remains incompletely understood. Recent studies have demonstrated that complement activation has multiple effects beyond target cell lysis, affecting both innate and adaptive immunity mediated by soluble complement fragments, such as C3a and C5a, and by stimulating complement receptors expressed by immune cells, including NK cells, neutrophils, macrophages, T cells, and dendritic cells. Complement activation can enhance ADCC and ADCP and may contribute to the vaccine effect of mAbs. These different aspects of complement are also briefly reviewed in the specific context of FDA-approved therapeutic anti-cancer IgG1 mAbs.